1. Patient-Centered Outcomes Research Institute (PCORI). Available at: http://www.pcori.org/home.html .
2. King, M. T. (2011). A point of minimal important difference (MID): A critique of terminology and methods. Expert review of pharmacoeconomics & outcomes research, 11(2), 171–184.
3. Food and Drug Administration. (2009). Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Federal Register, 74(235), 65132–65133.
4. Burke, L. B., & Trenacosti, A. M. (2010). Interpretation of PRO trial results to support FDA labelling claims: the regulator perspective. International Society for Pharmacoecomomics and Outcomes Research 15th Annual International Meeting. Atlanta: GA.
5. Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10(4), 407–415.